VIVUS (VVUS) : Meditor Group Ltd reduced its stake in VIVUS by 12.57% during the most recent quarter end. The investment management company now holds a total of 1,600,000 shares of VIVUS which is valued at $1,856,000 after selling 230,000 shares in VIVUS , the firm said in a disclosure report filed with the SEC on Jul 22, 2016.VIVUS makes up approximately 0.68% of Meditor Group Ltd’s portfolio.
Other Hedge Funds, Including , First Manhattan Co reduced its stake in VVUS by selling 1,500 shares or 3.5% in the most recent quarter. The Hedge Fund company now holds 41,400 shares of VVUS which is valued at $47,610.Creative Planning boosted its stake in VVUS in the latest quarter, The investment management firm added 101 additional shares and now holds a total of 8,456 shares of VIVUS which is valued at $9,724.
VIVUS opened for trading at $1.04 and hit $1.08 on the upside on Friday, eventually ending the session at $1.07, with a gain of 0.94% or 0.01 points. The heightened volatility saw the trading volume jump to 2,67,359 shares. Company has a market cap of $111 M.
On the company’s financial health, VIVUS reported $-0.12 EPS for the quarter, missing the analyst consensus estimate by $ -0.01 based on the information available during the earnings call on May 3, 2016. Analyst had a consensus of $-0.11. The company had revenue of $15.32 million for the quarter, compared to analysts expectations of $17.97 million. The company’s revenue was down -52.4 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $-0.15 EPS.
Many Wall Street Analysts have commented on VIVUS. VIVUS was Downgraded by WallachBeth to ” Hold” on May 4, 2016.
VIVUS Inc. is a biopharmaceutical company. The Company is engaged in the development and commercialization of therapeutic products. It provides two therapies approved by the Food and Drug Association (FDA) which include Qsymia (phentermine and topiramate extended-release) for chronic weight management and STENDRA (avanafil) for erectile dysfunction (ED). The Company is also developing and has completed the Phase II studies of Qsymia for the indication of OSA and diabetes. Qsymia is available in over 42000 certified retail pharmacies across the country. STENDRA is also approved by the European Commission (EC) under the name SPEDRA for the treatment of ED in the Europe. As of September 18 2014 the FDA approved a Supplemental New Drug Application (sNDA) for STENDRA. STENDRA is indicated to be taken approximately 15 minutes before sexual activity.